In this episode of the Healthcare India Podcast, Dr Vikram Venkateswaran explores the evolving landscape of healthcare funding in 2025. While global deal volumes are declining, mega-deals and acquisitions—particularly in AI-enabled healthcare—are keeping funding values high.

Closer to home, India has emerged as a healthcare investment hotspot. Healthtech funding reached $828M in H1 2025, with private equity investments of nearly ₹4,900 crore across 33 deals in Q2 alone.

Key highlights from this episode include:

• The $775M Manipal–Sahyadri Hospitals acquisition ahead of Manipal’s IPO.

• PB Healthcare’s $218M seed round led by General Catalyst—an ambitious integration of care delivery and insurance.

• ADIA’s $200M investment into Meril Micro Life Sciences, bolstering India’s medical device exports.

• Advent International’s $175M investment in Felix Pharmaceuticals signals rising interest in animal health.

• Truemeds’ $90M Series C round to consolidate the e-pharmacy space.

Dr Vikram shares strategic insights on what these deals mean for healthcare founders, investors, and the future of Indian healthcare. The key message: capital is available, but it’s concentrated—only scalable models with strong ROI and patient acquisition clarity will thrive.

🎧 Tune in to understand where healthcare funding is headed and how it will shape the sector in the years to come.